Concepedia

Elizabeth Dito

ED

Statistics

Publications

11

Citations

690

H-Index

11

Active since

2005

Affiliations

UCSF Helen Diller Family Comprehensive Cancer Center(Current)

University of California, San Francisco

Kaohsiung Medical University Chung-Ho Memorial Hospital

University of Utah

Huntsman Cancer Institute

Elizabeth Dito is an author at UCSF Helen Diller Family Comprehensive Cancer Center specializing in oncology, cancer therapeutics, and radiation oncology.

Top concepts

Publications per year

2005–2015

11

Publications

11

A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer

Andrew H. Ko, Margaret A. Tempero, Y-S Shan et al. · British Journal of Cancer · 2013 · 158 citations · Full text

A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma

Andrew H. Ko, Tanios Bekaii‐Saab, Jessica Van Ziffle et al. · Clinical Cancer Research · 2015 · 119 citations · Full text

A Phase II Study of Fixed-Dose Rate Gemcitabine Plus Low-Dose Cisplatin Followed by Consolidative Chemoradiation for Locally Advanced Pancreatic Cancer

Andrew H. Ko, Jeanne M. Quivey, Alan P. Venook et al. · International Journal of Radiation Oncology*Biology*Physics · 2007 · 108 citations

, , +8

A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer

Andrew H. Ko, Alan P. Venook, Emily K. Bergsland et al. · Cancer Chemotherapy and Pharmacology · 2010 · 72 citations

, , +7

Phase II Study of Fixed Dose Rate Gemcitabine With Cisplatin for Metastatic Adenocarcinoma of the Pancreas

Andrew H. Ko, Elizabeth Dito, Brian Schillinger et al. · Journal of Clinical Oncology · 2005 · 72 citations

1–5 of 11